Lilly posts $23b quarter as Mounjaro and Zepbound deliver $14.9b
Gross margin reached 86.3% and the company raised full-year revenue and non-GAAP EPS guidance after positive phase 3 retatrutide readouts.
TR
By Tom Reyes · Markets Editor
Aug 6 03:00 ETSource: Simply Wall Street
The wire
- 01Eli Lilly reported roughly US$23.0b in quarterly revenue and about US$8.40 non-GAAP EPS, with cardiometabolic drugs Mounjaro and Zepbound contributing about US$14.9b and some US$6.3b of year-on-year growth.
- 02The incretin franchise now carries the bulk of Lilly's profit, which shapes pricing, supply and contracting decisions that reach pharmacies and telehealth prescribers.
- 03The piece notes unresolved pressure points: drug pricing reform, employer pushback, a Medicaid judgment and 340B disputes, plus oral Foundayo trailing oral Wegovy in US prescriptions and not yet filed in Europe.
From the source
Read at simplywall.stEli Lilly (LLY) Stock Climbs On GLP 1 Strength And 86% Margin
Eli Lilly stock rose almost 5% today, even after a choppy week, as investors focused on one central idea. The earnings story is centered on profit power. Non GAAP earnings per share of about US$8.40 came on roughly US$23.0b in quarterly revenue and a very high gross margin near 86%. That combination is what pulled sentiment sharply higher in a single session, while the longer term chart had cooled
